Mizuho analyst Graig Suvannavejh initiates coverage on Adverum Biotechnologies (NASDAQ:ADVM) with a Buy rating and announces Price Target of $2.
Mizuho Initiates Coverage On Adverum Biotechnologies With Buy Rating, Announces Price Target of $2
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.